PainTEQ Featured on Business Observer Website

PainTEQ nearly tripled in size from 2019 to 2020, but our growth won’t stop there.

“Our goal is to try and double revenue every year,” PainTEQ’s chief commercial officer Shanth Thiyagalingam says. “We’re going to try and go for that $22 mark next year and we’re going to keep doubling from there. But more than that, we want to have good patient outcomes and invest in clinical evidence.”

Check out our feature on The Business Observer website where we share our new goals and objectives.

Read the full article: The Business Observer